Longevity & Aging · Metabolic & Cardiometabolic
multi-cancer early detection MCED blood tests such as Galleri detect early-stage cancers with high specificity but modest sensitivity
In plain terms: Can a blood test like Galleri catch early cancer accurately?
Specificity is genuinely high (about 99%) but sensitivity is low for early (stage I/II) disease and drops steeply by stage, so a negative result is weakly reassuring and no mortality benefit is yet shown.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
How the studies fall
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Jamshidi 2022 · Cancer Cell | observational | supports | moderate | CCGA methods substudy confirmed whole-genome methylation as best MCED approach at fixed 98-99% specificity, with sensitivity tracking circulating tumor fraction (low in early tumors). |
| Schrag 2023 · Lancet | observational | mixed | high | PATHFINDER prospective cohort of 6,662 adults >=50 found 99.5% specificity but only 1.4% cancer-signal-detected rate and PPV of 38%, confirming high specificity yet limited overall yield. |
| Marlow 2023 · BMJ Open | observational | contradicts | moderate | Qualitative study documented substantial psychological harm and diagnostic-odyssey burden from cancer-signal-detected results, tempering claims that MCED testing is straightforwardly accurate/beneficial. |
| Nicholson 2023 · Lancet Oncol | observational | mixed | high | SYMPLIFY (symptomatic patients): specificity 98.4% but sensitivity only 66% overall and 24% at stage I — confirming poor early-stage sensitivity even in enriched populations. |
| Bryce 2023 · JCO Precis Oncol | observational | mixed | moderate | CCGA substudy-3 symptomatic subgroup showed high specificity (~99.5%) but sensitivity rose steeply with stage, remaining low in stage I disease. |
| Khare 2025 · Front Oncol | observational | mixed | low | Single-institution PATHFINDER case series illustrated real-world true and false positives, reinforcing high specificity alongside meaningful false-positive workups. |
| Klein 2021 · Ann Oncol | observational | supports | high | CCGA validation: targeted-methylation MCED test achieved 99.5% specificity but overall sensitivity only about 51%, and far lower at stage I (about 17%) — high specificity, modest/stage-dependent sensitivity. |
| Neal 2022 · Cancers | RCT | mixed | high | NHS-Galleri design paper for a 140,000-participant RCT powered on late-stage incidence reduction, underscoring that specificity is established but clinical-utility/mortality benefit remains unproven. |
| Nadauld 2021 · Cancers (Basel) | observational | mixed | moderate | PATHFINDER real-world implementation projected PPV only about 49% (many signals need extensive workup), tempering the high-specificity-solves-false-positives framing at population prevalence. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.